Background and purpose: Stroke is a major cause of neonatal morbidity, often with delayed diagnosis and with no accepted therapeutic options. The purpose of this study is to investigate the efficacy of delayed initiation of multiple dose erythropoietin (EPO) therapy in improving histological and behavioral outcomes after early transient ischemic stroke. Methods: 32 postnatal day 10 (P10) Sprague-Dawley rats underwent sham surgery or transient middle cerebral artery occlusion (tMCAO) for 3 h, resulting in injury involving the striatum and parieto-temporal cortex. EPO (1000 U/kg per dose × 3 doses) or vehicle was administered intraperitoneally starting one week after tMCAO (at P17, P20, and P23). At four weeks after tMCAO, sensorimotor function was assessed in these four groups (6 vehicle-sham, 6 EPO-sham, 10 vehicle-tMCAO and 10 EPO-tMCAO) with forepaw preference in cylinder rearing trials. Brains were then harvested for hemispheric volume and Western blot analysis. Results: EPO-tMCAO animals had significant improvement in forepaw symmetry in cylinder rearing trials compared to vehicle-tMCAO animals, and did not differ from sham animals. There was also significant preservation of hemispheric brain volume in EPO-tMCAO compared to vehicle-tMCAO animals. No differences in ongoing cell death at P17 or P24 were noted by spectrin cleavage in either EPO-tMCAO or vehicle-tMCAO groups. Conclusions: These results suggest that delayed EPO therapy improves both behavioral and histological outcomes at one month following transient neonatal stroke, and may provide a late treatment alternative for early brain injury.
Introduction
Stroke during the neonatal period is a significant cause of death and long-term disability, occurring in as many as 1 in 2300 live births (Grunt et al., 2015) . Most survivors have long-term motor or cognitive dysfunction, yet despite these lifelong effects no accepted post-injury treatment exists. In addition, many cases are identified outside of the perinatal period, which further complicates therapeutic strategies as effective treatments initiated remotely from the insult would be necessary to benefit many affected infants.
It is clear that injury continues to progress over a period of days to weeks following the primary insult (van der Aa et al., 2013) . This involves a variety of mechanisms and pathways that result in early necrosis and later programmed cell death, as well as decreased cell proliferation and altered cell fate. Of many potential therapies that have been studied in an effort to both suppress early cell death but also enhance later proliferation and repair, erythropoietin (EPO) has shown promise in a number of brain injury models. EPO is a pleiotropic cytokine with a number of erythropoietic and non-erythropoietic roles (Wu and Gonzalez, 2015) . EPO and EPO receptor (EPO-R) expression are elevated in the brain during gestation but decline rapidly after birth, with cell-specific endogenous EPO/EPO-R upregulation after injury (Bernaudin et al., 1999) . Following hypoxia there is stabilization of HIF-1, with increased expression of downstream targets and growth factors that include EPO and VEGF (Bernaudin et al., 2002; Mu et al., 2005) . This results in specific expression of EPO and its receptor on neurons, astrocytes and microglia at different time points that initiate endogenous mechanisms for neuroprotection and repair (Bernaudin et al., 1999) . Initiation of these intracellular processes lead to antiapoptotic, anti-inflammatory and pro-angiogenic effects, and play a significant role in neurogenesis and cell fate outcome (Xiong et al., 2011) .
We have previously described a non-hemorrhagic ischemiareperfusion stroke model in the immature rat using transient middle cerebral artery occlusion (tMCAO) (Derugin et al., 1998; Gonzalez et al., 2013) . This is similar to the most common cause of stroke in the perinatal period (Rutherford et al., 2012; van der Aa et al., 2014) . We have demonstrated increased cell proliferation and migration from the subventricular zone (SVZ), with altered cell fate favoring newly born Neurobiology of Disease 93 (2016) 57-63 
